Study of Dextromethorphan in OCD and Related Disorders
Key facts
- Who runs it
- Stanford University
- Where
- Stanford, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 20 Jan 2022
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Fluoxetine
- Dextromethorphan
- Record updated
- 20 May 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
- Living within California
- Capacity to provide informed consent
Who cannot take part
- Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
- Current bipolar disorder or psychotic disorder
- Active moderate or severe substance use disorder, lifetime severe substance use disorder
- Pregnant or nursing women
- Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Stanford UniversityStanford, United StatesContact: Alessa Gaeta, BATaking people
About the trial
What the trial wants to find out
The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.
The 2 groups in the trial
- Group A: fluoxetine then fluoxetine plus dextromethorphanTreatment being tested
Group A participants will take fluoxetine 20mg (or prior dose) daily for 4 weeks, and will then continue fluoxetine while adding over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks.
Treatment: Fluoxetine and Dextromethorphan
- Group B: fluoxetine plus dextromethorphan then fluoxetineTreatment being tested
Group B participants will take fluoxetine 20mg (or prior dose) daily together with over the counter dextromethorphan, with doses increasing weekly as tolerated, for 4 weeks, and then will stop dextromethorphan, continuing fluoxetine alone for 4 weeks.
Treatment: Fluoxetine and Dextromethorphan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study
- Fit questions
- Built from NCT04899687, who can take part
- Record updated
- 20 May 2026